Combination therapies for the treatment of cancer

Abstract

A method for treatment or prophylaxis of benign prostatic hyperplasia by administration of lonidarrine or a lonidamine analog is provided. Also provided are unit dosage forms of lonidamine or an analog, useful for such treatment and prophylaxis.

Description

[0001] Cross References to Related Applications [0001] This application claims the benefit of the following U.S. Provisional Applications: U.S. Provisional Application Nos. 60 / 496,163 (filed August 18, 2003), 60 / 488,265 (filed July 18, 2003), 60 / 472,907 (filed May 2003) 22), 60 / 460,012 (filed 2 April 2003), 60 / 458,846 (filed 28 March 2003), 60 / 458,665 (filed 28 March 2003), 60 / 458,663 60 / 442,344 (filed January 23, 2003), and 60 / 441,110 (filed January 17, 2003), each of which is hereby incorporated in its entirety by Included as a reference for all topics. technical field [0002] The invention relates to the treatment and prevention of benign prostatic hyperplasia, and is applied in the field of medicine and related fields, including the field of chemistry, medical chemistry, and molecular biology. Background technique [0003] Benign prostatic hyperplasia (BPH), a disease in which abnormal growths of prostate epithelial cells block urine flow, afflic...

AI Technical Summary

Problems solved by technology

Although this class of drug reduces symptoms more quickly than the first class of drugs, it does not reduce the size of the prostate, or prevent it from becoming larger, which can lead to eventual surgical intervention

[0005] Therefore, there is a clear, unmet need for drugs that can treat the underlying disease state of BPH without serious side effects

Images